DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
D’Angelo SP, Russell JS, Bhatia S. et al.
18 month efficacy and safety update from JAVELIN Merkel 200 part A. A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.
Journal of Clinical Oncology 2018;
DOI: 10.1200/JCO.2018.36.5_suppl.192.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.